Actionnariat et activité des initiés pour Canopy Growth Corporation (CGC): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $0.92 |
| Capitalisation | $387M |
| Bourse | NASDAQ |
| Pays | CA |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-08-24 | Gedeon Christelle | S-Sale | 13,344 | $20K |
| 2026-08-24 | Stewart Thomas Carlton | S-Sale | 2,231 | $3K |
| 2026-06-26 | BAYERN JOSEPH | S-Sale | 3,197 | $3K |
| 2026-06-26 | Yanofsky Theresa | S-Sale | 15,054 | $14K |
| 2026-06-26 | ATKINS M SHAN | S-Sale | 3,197 | $3K |
| 2026-06-26 | Lazzarato David Angelo | S-Sale | 22,674 | $21K |
| 2026-06-17 | ATKINS M SHAN | A-Award | 108,324 | |
| 2026-06-17 | Lazzarato David Angelo | A-Award | 162,485 | |
| 2026-06-17 | BAYERN JOSEPH | A-Award | 108,324 | |
| 2026-06-17 | Yanofsky Theresa | A-Award | 108,324 |
Bilan (10 ans)
| Année | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $101.8M | $322.6M | $2.48B | $915.6M | $1.15B | $776.0M | $667.7M | $170.3M | $113.8M | $364.7M |
| Placements à Court Terme | 0 | 0 | $2.06B | $488.2M | $1.16B | $595.7M | $105.5M | $33.2M | $17.7M | $5.1M |
| Créances | $5.8M | $21.4M | $107.0M | $63.3M | $67.1M | $86.6M | $68.5M | $51.8M | $52.8M | $36.3M |
| Stocks | $60.7M | $118.0M | $190.1M | $274.8M | $369.5M | $204.5M | $83.2M | $77.3M | $96.4M | $154.1M |
| Actifs Courants | $178.8M | $481.8M | $4.92B | $1.80B | $2.84B | $1.73B | $1.08B | $371.2M | $294.6M | $529.5M |
| Immobilisations Corporelles | $96.3M | $303.7M | $1.10B | $1.07B | $1.07B | $942.8M | $471.3M | $320.1M | $293.5M | $441.4M |
| Goodwill | $241.4M | $314.9M | $1.54B | $1.37B | $1.89B | $1.87B | $85.6M | $43.2M | $46.0M | $77.7M |
| Actifs Incorporels | $162.3M | $101.5M | $519.6M | $334.7M | $308.2M | $252.7M | $160.8M | $104.1M | $87.2M | $128.9M |
| Actifs Totaux | $677.6M | $1.44B | $8.73B | $4.82B | $6.82B | $5.61B | $2.44B | $1.30B | $917.7M | $1.12B |
| Dettes Fournisseurs | $5.7M | $46.2M | $188.9M | $86.7M | $67.3M | $64.3M | $31.8M | $28.7M | $26.1M | $34.8M |
| Dette à Court Terme | $1.7M | $1.6M | $103.7M | $39.9M | $9.8M | $9.3M | $556.9M | $103.9M | $4.3M | $16.2M |
| Passifs Courants | $17.7M | $92.0M | $411.7M | $295.5M | $284.3M | $213.2M | $803.8M | $234.7M | $94.4M | $158.4M |
| Dette à Long Terme | $8.6M | $6.9M | $842.3M | $315.5M | $1.57B | $1.49B | $750.0M | $493.3M | $299.8M | $217.1M |
| Passifs Totaux | $62.9M | $193.6M | $1.49B | $1.18B | $3.20B | $1.98B | $1.68B | $799.8M | $430.5M | $421.1M |
| Réserves | -$21.3M | -$91.6M | -$835.1M | -$3.04B | -$6.07B | -$6.38B | -$9.67B | -$10.33B | -$10.93B | -$11.14B |
| Capitaux Propres | $639.8M | $1.16B | $6.78B | $3.43B | $3.48B | $3.58B | $758.4M | $500.4M | $487.2M | $697.6M |
| Dette Totale | $10.3M | $8.4M | $946.0M | $439.7M | $1.72B | $1.64B | $1.41B | $668.0M | $348.4M | $278.7M |
| Dette Nette | -$91.5M | -$314.1M | -$3.60B | -$964.1M | -$598.3M | $268.5M | $640.5M | $464.5M | $216.9M | -$92.0M |
| Fonds de Roulement | $161.1M | $389.7M | $4.51B | $1.51B | $2.55B | $1.51B | $273.4M | $136.5M | $200.2M | $371.0M |
Santé financière
| Dette / Capitaux propres | 0.40 |
| Ratio de liquidité | 3.04 |
Rentabilité
| Rentabilité des capitaux propres | -29.85% |
| Rentabilité du capital investi | -15.31% |
| Rentabilité des actifs | -21.43% |
| Marge brute | 22.87% |
| Marge opérationnelle | -46.89% |
| Marge nette | -73.95% |
Entreprises liées: ACB · ACRS · BIOA · CABA · DH · IRWD · LFCR
Explorer le secteur: Healthcare · Drug Manufacturers - Specialty & Generic
Plus de sections de CGC: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions